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Background. In 1997, Stoppini et al reported that monoclonal
antibody specific to the C-terminal 92–99 of b 2-microglobulin
(b 2m) had been capable of inhibiting fibrillogenesis of b 2m in
vitro. Meanwhile, recent studies have indicated that an acidify-
ing procedure can unfold conformation of the precursor protein,
leading to fibril formation of b 2m as well as a transthyretin.
Methods. We thus prepared monoclonal antibody specific to
the C-terminal 92–99 (mAb 92–99), and investigated its reactiv-
ity in plasma ultrafiltrate and amyloid tissues from 18 hemodial-
ysis patients with dialysis-related amyloidosis (DRA).
Results. b 2m extracted from ultrafiltrate showed no reaction
for mAb 92–99, whereas acidified b 2m from ultrafiltrate showed
a reaction for mAb 92–99. Similarly, a homogenate of carpal
amyloid tissues showed a strong reaction for mAb 92–99 on im-
munoblotting. Immunohistochemical study showed also a dis-
tinct staining for mAb 92–99 in 7 Congophilic specimens from
DRA patients. More interestingly, staining for mAb 92–99 could
be found in most, though not all, non-Congophilic tissues.
Conclusion. This study demonstrates that the monoclonal
antibody specific to the C-terminal 92–99 of b 2m can detect
the conformational intermediate in amyloidogenesis of b 2m
ex vivo, and demonstrates that an unfolded b 2m at C-terminal
could be found not only in Congophilic area but even in non-
Congophilic area as well.
b 2-microglobulin (b 2m) was identified as the precursor
protein of dialysis-related amyloidosis (DRA) by Gejyo
et al [1] in 1985. This protein is composed of 99 amino
acids and shows a seemingly simple appearance in the
plane dimension, but a complex conformation involving
7 b-strands in a 3-dimensional configuration that was de-
termined by Becker and Reeke [2] in the same year. In the
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physiologic condition, a free b 2m molecule is distributed
over an extracellular space exclusively in a monomeric
form, which is constantly shed from the cellular mem-
brane.
Up until now, several variants of b 2m have been re-
ported in clinical specimens, including amyloid tissues
from hemodialysis (HD) patients [3, 4], but unfolded vari-
ants have not yet been reported in a clinical setting, except
for an abstract document by Rampino et al [5]. Stoppini
et al [6] reported that carpal amyloid tissue from HD pa-
tients was positive for a monoclonal antibody specific to
the C-terminal octapeptide, residues 92–99, of b 2m, as
well as to a commercial polyclonal anti-b 2m serum in the
physiologic state. This C-terminal portion is considered
to be normally hidden in the core of the quaternary struc-
ture of the MHC-I complex, and therefore regarded as
being nonreactive with commercial polyclonal anti-b 2m
serum. Using this monoclonal antibody of b 2m (mAb
14H3), Rampino et al [5] found that a significant increase
of 92–99 epitope expression on monocytes was induced
by hemodialysis.
On the other hand, Hoshino et al [7] reported that
the N- and C-terminals are excluded from the amyloid
core formed in vitro by the seed-dependent extension re-
action. In an analogous study on partially folded b 2m,
McParland et al [8] described that dissociation of the N-
and C-terminal strands from the core of native b 2m is
sufficient to initiate amyloid formation.
Based upon those provocative reports, we speculate
that the unfolding in the C-terminal portion might be a
potential process of fibrillar transition (i.e., amyloidoge-
nesis) of b 2m. We thus also prepared a specific mono-
clonal antibody for the C-terminal epitope 92–99 residue
of b 2m, referred to as mAb 92–99 in this paper, and inves-
tigated its reactivity with b 2m from an ultrafiltrate, and
with b 2m in amyloid tissues from HD patients with DRA.
A basic study concerning the misfolding process of b 2m
has been reported by MacParland et al, Kozhukh et al
and Naiki et al [8, 9, 10], but to our knowledge, no report
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concerning misfolded b 2m has yet been published in an
HD setting.
METHODS
Materials
Commercial chemicals, except where indicated, other-
wise were purchased from Wako Chemical Co. (Osaka,
Japan).
Synthesis of peptide corresponding to human
b2m C-terminal
The peptide identical with the C-terminal octapep-
tide of b 2m was synthesized by an automated ma-
chine (model 430A; Applied Biosystems, Foster City,
CA, USA) using solid-phase techniques. Using butoxy-
carbonyl (Boc) as a protector, Boc-Cys(MeBzl)-Ile-Val-
Lys(ClZ)-Trp-Asp(chex)-Arg(Tos)-Asp(chex)-Met was
synthesized and purified by reversed-phase chromatog-
raphy using an ODS column (ODS-D-5, 2 cm × 25 cm;
YMC Co., Ltd., Kyoto, Japan). The peptide was coupled
to keyhole limpet hemocyanin (KLH; Calbiochem, CA,
USA) by m-maleimidobenzoyl-N-hydroxysuccinimide
ester (MBS; Pierce, Rockford, IL, USA) [11] and applied
as an immunogen to mice.
Mass analysis of the synthesized peptide
Mass spectrometer used in the experiments was a
home-built linear time-on-flight instrument (TOF-MS)
equipped with a nitrogen laser emitting at 337 nm
(LASERMAT; Finnigan MAT, San Jose, CA, USA). Ex-
clusively positively charged ions were analyzed, and 28
single-shot spectra were accumulated.
Amino acid analysis
The b 2m 92–99 peptide was hydrolyzed in 1% phe-
nol in 6 mol/L HCl for 1 hour at 150◦C, and then dried
and subjected to amino acid analysis using Waters 600E
HPLC system (Waters Co., Milford, MA, USA), ODS-R5
column (YMC Co., Ltd.).
Preparation of monoclonal antibody
Monoclonal antibody was prepared according to a
modified method by Galfre and Milstein [12]. Briefly,
Balb/c mice were injected subcutaneously with 0.5 mg
of KLH-coupled peptide in 50% Freund’s complete ad-
juvant. After the first immunization, 2 boosters were in-
jected using 0.25 mg of KLH-coupled peptide in 50%
Freund’s complete adjuvant every 2 weeks. The splenic
lymphocytes from the immunized mice were fused to
myeloma P3U1 cells in the presence of polyethylene
glycol. Hybrid cells were cultured in a medium con-
taining aminopterin, hypoxanthine, and thymidine (HAT
medium) with 10% fetal calf serum. The cell lines were
selected and then injected into Balb/c mice to produce
ascites fluid. Antibody was precipitated from cell-free as-
cites fluid with ammonium sulfate (40% saturation).
Direct ELISA
The reactivity and specificity of mAb 92–99 was con-
firmed by direct enzyme-linked immunosorbent assay
(ELISA). Each well was incubated at 37◦C for 60 minutes
with 0.05 mL of the above peptide (1 lg/mL) in 10 mmol/L
phosphate-buffered saline (PBS, pH 7.4) and washed
3 times with PBS (pH 7.4) containing 0.05% Tween 20
(washing buffer). Each well was then blocked at 37◦C for
1 hour with 0.3 mL of Block Ace (Dainippon Pharma-
ceutical, Osaka, Japan). Each well was washed 3 times
with washing buffer, and incubated at 37◦C for 1 hour
with 0.05 mL of monoclonal antibody. Wells were washed
3 times with washing buffer, and incubated at 37◦C for
1 hour with 0.05 mL of biotinylated antimouse IgG anti-
body and reacted with avidin-biotin alkaline phosphatase
complexes (vectastain ABC kit; Vector, Burlingame, CA,
USA), followed by reaction with p-nitrophenylphosphate
(Bio-Rad, Hercules, CA, USA). The reaction was termi-
nated with 0.4 N NaOH, and an absorbance was detected
by the electroimmunoassay (EIA) reader (model 2550;
Bio-Rad) at 405 nm. As an unrelated antibody, we used
a monoclonal antibody for b 2m 4559 [13].
Competitive ELISA
The specificity of mAb 92–99 was also confirmed by
competitive ELISA. A well was coated with 0.05 mL of
synthesized peptide (1 lg/mL) diluted in 10 mmol/L PBS
(pH 7.4) and incubated at 37◦C for 1 hour. After wash-
ing, the well was blocked with Block Ace (Dainippon
Pharmaceutical) at 37◦C for 1 hour. After washing, a
quantity of 0.1 mL of synthesized peptide, acidified b 2m,
or re-b 2m in 10 mmol/L PBS (pH 7.4), reacted with
0.05 mL of biotinylated mAb 92–99 (50 lg/mL) at 37◦C
for 1 hour, was added to well. The well was incubated at
37◦C for 1 hour and then washed 3 times. After addition
of 0.05 mL of avidin-biotin alkaline phosphatase com-
plexes (Vectastain ABC kit; Vector), the reaction was
stood at 37◦C for 1 hour, followed by reaction with p-
nitrophenylphosphate (Bio-Rad). The reaction was ter-
minated with 0.4 N NaOH, and the absorbance was
detected by an EIA reader (model 2550; Bio-Rad) at
405 nm.
Extraction of b2m from plasma ultrafiltrate
from HD patient
One hundred and thirty mL of ultrafiltrate was ob-
tained by hemofiltration from the HD patient (H.M., 62
years of age, female, maintained on HD for 15 years, and
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consenting to take part in our study). The b 2m fraction
was isolated by affinity chromatography in a Formyl cel-
lulofine Sephacryl S column, and subsequently, a con-
taminated albumin was removed by a gel filtration with
Sephacryl S column (data not shown). The affinity chro-
matography conditions were as follows: used as the elu-
ent was 100 mmol/L glycine-HCl buffer, pH 2.5, at a flow
rate of 0.95 mL/min. Detection was done at 280 nm. The
conditions for gel filtration were as follows: used as the
eluent was 50 mmol/L PBS buffer (pH 7.4) at a flow rate
of 1 mL/min (data not shown).
Acidification of b2m isolated from ultrafiltrate
An aliquot of b 2m isolated from ultrafiltrate was dis-
solved in 50 mmol/L Tris-HCl buffer, and then acidified
by adding 4 lL (pH 3.0) of 6 N HCl.
Circular dichroism (CD)
The CD spectra of b 2m were recorded on an Aviv
model Jasco J-600 spectrometer (Jasco, Inc., Easton, MD,
USA) at 25◦C using a bandwidth of 0.5 nm, a time con-
stant of 2 seconds, and a step size 0.2 nm employing 4
averages. b 2m solutions 20 mmol/L at the desired pH
(50 mmol/L Tris-HCl in 100 mmol/L NaCl) were pre-
pared. The far-UV CD spectra were recorded from 200
to 240 nm using a 1 mm quartz cell.
Immunoblotting
In general, separation and identification of protein
has been conventionally carried out by sodium dodecyl
sulfate-polyacrylamide gel (SDS-PAGE) electrophoresis,
but SDS is known to cause intrinsically an unfolding of
native proteins. So, we investigated the reactivity of mAb
92–99 with b 2m from various specimens by immunoblot-
ting, a method that makes it possible to detect sponta-
neous reaction in liquid ambient.
Immunohistochemistry
An immunohistochemical study using both mAb 92–
99 and polyclonal anti-b 2m serum were carried out on
12 carpal tunnel tissues, 5 coracoacrominal tendons re-
moved by endoscopic surgery, and 1 lumbar disc from
an autopsy on a patient who had been on HD. The sec-
tions were immunostained by the avidin-biotin complex
(ABC) method (Dako, Glostrup, Denmark) as described
elsewhere [14]. Briefly, the sections were incubated with
an ABC solution (dilution 1:50) at room temperature
for 30 minutes. Peroxidase was detected by immersing
the sections in 50 mL TRIS buffer containing 25 mg di-
aminobenzidine tetrahydrochloride and 10 lL of 30%
H2O2 followed by light counterstaining in Mayer’s hema-
toxylin.
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Fig. 1. MALDI mass spectra of synthesized peptide.
Patients
Enrolled in this study were 18 HD patients, aged 38
to 68 years old, all of whom had undergone surgery for
carpal tunnel syndrome. The primary disease was nondi-
abetic in 6 patients, diabetic in 3 patients, and of unclear
etiology in 9 patients. Duration of HD was 17.7 years on
average, varying from 4 to 29 years.
Biotin labeling of antibody
Biotinylation of mAb 92–99 or anti-b 2m polyclonal an-
tibody was performed using sulfosuccinimidyl D-biotin
(Biotin Sulfo-Osu; Dojindo, Kumamoto, Japan).
RESULTS
Identification of the synthesized peptide
To confirm whether the synthesized peptide was iden-
tical to the C-terminal octapeptides of b 2m, Ile-Val-Lys-
Trp-Asp-Arg-Asp-Met, mass spectrometric and amino
acid analyses were performed.
The resulting mass spectrum of the peptide is shown
in Figure 1. The peptide was identified by this analysis
as one peak at Mr 1166, which was consistent with the
calculated molecular weight of the peptide (Mr 1164).
A commercial renin substrate (Asp-Arg-Val-Tyr-Ile-His-
Pro-Phe-His-Leu-Leu-Val-Tyr-Ser; Mr 1760; Sigma, St.
Louis, MO, USA) was used as an internal standard for
mass analysis.
The mole ratio of the amino acids in the peptide was al-
most identical to the theoretical content of the C-terminal
portion of b 2m, except for the lack of tryptophan, which
had been degraded in this procedure (Table 1).
Specificity of the prepared monoclonal antibody
In direct ELISA, the synthesized peptide reacted dose
dependently with the prepared monoclonal antibody,
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Fig. 2. Specificity of the prepared monoclonal antibody with direct ELISA (A) and competitive ELISA (B). In (A), black circles (•) indicate reaction
by mAb 92–99 against synthesized b 2m 92–99 peptide, triangle mark () indicates reaction by polyclonal anti-b 2m serum against synthesized b 2m
92–99 peptide, (×) mark indicates a reaction by b 2m-monoclonal antibody 4559 against synthesized b 2m 92–99 peptide. In (B), black circles (•)
indicate competition with the synthetic peptide, triangle mark () indicates competition with the acidified-b 2m, and square mark () indicates
competition with the re-b 2m.
Table 1. Mole ratios of the amino acid constituents of the synthesized
peptide
A.A Expected Found
ASX 2.0 2.5
ARG 1.0 1.2
VAL 1.0 0.8
MET 1.0 1.0
ILE 1.0 0.8
LYS 1.0 0.9
CYS 1.0 –
TRP 1.0 –
The amount of each amino acid of the synthesized peptide, derived b 2m
92–99, was measured by amino acid analysis as described in Methods. Amino
acid analysis was performed once.
but not with the commercial-based polyclonal anti-b 2m
serum (Fig. 2A).
In competitive ELISA with the synthetic peptide, acid-
ified b 2m from the ultrafiltrate and the re-b 2m as com-
petitors, marked inhibition could be found even at low
concentrations of the synthetic peptide, and definite in-
hibition was detectable in the case of the acidified b 2m
in 100 lg/mL or more. By contrast, no inhibition was ob-
servable at any concentration of a re-b 2m. The Kd value
calculated on the basis of the data obtained with compet-
itive ELISA was 2.16 ×10−10 mol/L, according to Friguet
et al [15] (Fig. 2B).
Immunoblotting
Both the serum b 2m and the b 2m extracted from the ul-
trafiltrate showed a negligible reaction with mAb 92–99.
In contrast, the b 2m denatured by acidification showed a
weak, but distinct reaction with mAb 92–99. The b 2m in
homogenate of the amyloid tissue showed a strong reac-
tion for mAb 92–99 (Fig. 3).
CD spectra of denatured b2m by acidification
The CD spectra of acidified b 2m from ultrafiltrate
showed a loss of the positive peak at 205 nm and sift
of the minimum at 218 nm, which was definitely different
from the CD spectra of native b 2m (Fig. 4).
Immunohistochemistry
In all specimens studied, b 2m accumulation was con-
firmed immunohistochemically with a polyclonal anti-
b 2m serum. Seven specimens from the carpal tissue
were Congo red–positive, and another 11 specimens were
Congo red–negative. Two of the Congo red–positive spec-
imens also had non-Congophilic areas. On the one hand,
a distinct staining of mAb 92–99 was recognized, and this
was the case, without exception, with all Congophilic ar-
eas. On the other, no staining of mAb 92–99 was recog-
nized in the areas not stainable with Congo red in those
specimens (Fig. 5).
By contrast, a distinct staining of mAb 92–99 was
discoverable even in those specimens that were predom-
inantly non-Congophilic, although several of the non-
Congophilic areas remained negative for mAb 92–99
(Fig. 6).
DISCUSSION
b 2m was reported as the fifth precursor protein in amy-
loidosis soon after b amyloid peptide had been identified
in Alzheimer’s disease, and its amyloidogenicity was di-
rectly witnessed in an in vitro study by Connors et al in
1985 [1, 16]. Stoppini et al [6] prepared 3 kinds of mon-
oclonal antibody for a fibril b 2m aggregate according to
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Fig. 3. Immunoblotting for various speci-
mens. Serum (A), acidified b 2m of ultrafiltrate
from HD patient’s plasma (B), b 2m of the ul-
trafiltrate from HD patient’s plasma (C), ho-
mogenate from carpal tissue (D and E).
Connors’s report [16], and determined the localization
of each epitope, respectively. Among these epitopes, the
epitope of the monoclonal antibody mAb14H3 was iden-
tified to be the C-terminal 92–99 portion. In addition, it
has been reported that b 2m within MHC-I on peripheral
mononuclear cells was not recognized by mAb14H3, indi-
cating that the C-terminal 92–99 portion might be folded
inside the molecule, and might be cryptic in the physio-
logic state. Accordingly, a reaction with this cryptic epi-
tope can be interpreted to indicate, at least, a partially
unfolded b 2m whose population was described as being
important in amyloid fibril formation by McParland et al
[8].
Although the mechanism of amyloid formation (i.e.,
fibrillogenesis) remains to be fully clarified, recent stud-
ies indicate that an unfolded molecular form might be a
key intermediate in fibrillogenesis [8, 17, 18]. b 2m was
demonstrated to show a pH-dependent unfolding transi-
tion, and to most likely form an amyloid fibril at pH 3.6 [8]
or at a pH of around 2.5 [9, 10]. A similar effect of acidifi-
cation had been originally reported in TTR, a precursor
protein in the familiar amyloid polyneuropathy [19].
Taking these findings into account, it can be concluded
that the fact that the reactivity of our monoclonal anti-
body is almost exclusively limited to acidified b 2m from
ultrafiltrate may be considered evidence to indicate its po-
tential availability for detection of the partially unfolded
b 2m (i.e., conformational intermediate in amyloidogen-
esis of b 2m).
So far, a variety of heterogeneous forms of b 2m have
been reported in patients with DRA, but no study con-
cerning misfolding of b 2m in vivo appears to have been
carried out except for the ex vivo study by Bellotti et al
[17]. It may be of particular interest to note that the
majority of those areas that lacked Congo red staining
50
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Fig. 4. Circular dichroism pattern of b2m isolated from plasma ultra-
filtrate. Dotted line indicates pH 7.0 (a loss of the peak at 205 nm), and
solid line indicates pH 3.0 (a shift of the minimum at 218 nm).
still showed a positive staining not only of polyclonal
anti-b 2m, but also of mAb 92–99. The coexistence of an
unfolded and native b 2m in non-Congophilic tissue is
presumably understood to indicate an involvement of an
unfolding in the C terminal in amyloidogenesis of this pre-
cursor protein. It has been reported that an accumulation
of native b 2m precedes the development of an amyloid
b 2m deposit [20, 21]. Similarly, preamyloid accumulation
of precursor protein was recognized in TTR transgenic
mice [22]. Taking into account these reports, the pres-
ence of the b 2m with an unfolded C-terminal in non-
Congophilic tissue might also be interpreted to indicate
that the unfolding in the C-terminal precedes fibril for-
mation of b 2m.
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AB
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Fig. 5. Immunostaining and histologic study
for amyloid deposist in carpal tissue from HD
patient (65 years old, female, 14 years of HD
duration). Immunostaining polyclonal anti-
b 2m serum (A). Both the area indicated by the
square frame and by the arrowhead show an
accumulation of b 2m. Congo red staining (B).
An area indicated by the square frame shows
a distinct red color. Polarizing microscopy of
Congo red staining (C). An area indicated
by the square frame shows a distinct yellow-
green birefringence, but an area indicated by
the arrowhead in (B) shows no polarized light
at all. Immunostaining with mAb 92–99 (D).
An area indicated by the square frame shows
a presence of b 2m with unfolded C-terminus.
By contrast, an area indicated by the arrow-
head shows a lacking of b 2m with unfolded
C-terminus.
Polyclonal antibody Congo red mAb 92-99
Polyclonal antibody Congo red mAb 92-99
B
A
Fig. 6. Immunostaining and histologic study for amyloid deposist in corocoacrominal ligament from an HD patient 38 years old, male, 19 years of
HD duration (A), and an HD patient 55 years old, female, 12 years of HD duration (B). Congo red stain: negative, mAb92-99 stain: positive (A);
Congo red stain: negative, mAb 92–99 stain: negative (B).
Bellotti et al reported that b 2m extracted from the
amyloid tissue in the femoral bone contained a transi-
tional intermediate molecule that was capable of show-
ing reversibly normal spectra both of the intrinsic
tryptophan fluorescence and on the circular dichroism
[17].
However, we are still not sure whether the accumu-
lation of unfolded C-terminal b 2m in non-Congophilic
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tissue is indicative of the preamyloid state, capable of re-
folding or not.
No matter where the folding takes place, whether in-
side or outside of the cells, there are various kinds of
amyloid-related structures, including disordered aggre-
gates and prefibrillar species, as suggested in a recent re-
view by Dobson [23]. These structures may be involved in
misfolding process, leading to amyloid fibril in vivo. Most
of these structures may be regarded as being unfolded. It
is therefore not possible to conclude from this study that
the b 2m detected by mAb 92–99 in the non-Congophilic
area must be one of the preamyloid intermediates. As of
now, neither the clinical significance nor the biological
potential of unfolding of C-terminal remains to be seen,
but our data on acidified b 2m suggests that it might be
theoretically possible.
As to a molecular insight of the amyloidogenicity of
b 2m, Kozhukh et al, and subsequently, Hoshino et al [7],
have reported that the mid-22 residue from 20serine to
41lysine referred to as K3 has a potential to form an amy-
loid core. Moreover, amyloidogenicity of the C-terminal
28 peptides, per se, has been confirmed by Ivanova et al
[24] very recently. What molecular structure is the key
intermediate of amyloidogenesis of b 2m, and which in-
termediate is reversible remain unclear, but we believe
that an unfolding in the C-terminal might be essentially
involved in amyloidogenesis of this molecule, and that an
unfolding in the C-terminal might also be an antecedent
to the formation of amyloid b 2m.
CONCLUSION
On the whole, this study shows that an unfolding of
the C-terminal of b 2m is taking place not only in Con-
gophilic but also in non-Congophilic tissue in vivo and,
thus, provides evidence in support of the prevalent hy-
pothesis that accumulation of the native b 2m precedes
the development of DRA in HD patients.
We hope that this study offers a new approach to a bet-
ter understanding of the pathomechanism of b 2m-related
amyloidosis in the dialysis setting.
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